The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD

H E Seaman, Corinne S de Vries, R D T Farmer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the treatment of women with acne and hirsutism and is a treatment option for polycystic ovary syndrome (PCOS). It acts as a contraceptive also.

Methods: Using the General Practice Research Database, we conducted a cohort analysis and case-control study in women aged 15-39 with acne, hirsutism or PCOS to estimate the risk of liver disorders associated with CPA/EE.

Results: Compared with cases exposed to conventional combined oral contraceptives (COCs), the age-adjusted incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (95%CI: 0.9,3.4) and compared with no use it was 1.5 (95%CI: 0.8, 2.8). In the case-control study, the adjusted odds ratio (OR) for liver disorders in women exposed to CPA/EE was 1.6 (95%CI: 0.7, 3.5) and 0.8 (95%CI: 0.5, 1.3) for exposure to conventional COCs, compared with no use. The risk of liver disorders in women prescribed CPA/EE was not significantly greater than that in women prescribed conventional COCs (OR: 2.1 [95%CI: 0.9, 4.8]).

Conclusion: Our results do not indicate an increased risk for liver disorders associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting for potential confounding. This may be due to lack of statistical power.

Original languageEnglish
Pages (from-to)541-550
Number of pages10
JournalPharmacoepidemiology and Drug Safety
Volume12
Issue number7
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Cyproterone Acetate
Ethinyl Estradiol
Case-Control Studies
Contraceptives, Oral, Combined
Liver
Hirsutism
Polycystic Ovary Syndrome
Acne Vulgaris
Odds Ratio
Contraceptive Agents
General Practice
Cohort Studies
Databases
Incidence
Therapeutics
Research

Cite this

The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD. / Seaman, H E; de Vries, Corinne S; Farmer, R D T.

In: Pharmacoepidemiology and Drug Safety, Vol. 12, No. 7, 10.2003, p. 541-550.

Research output: Contribution to journalArticle

@article{4525024646f94112b363a5fead60791c,
title = "The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD",
abstract = "Purpose: To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the treatment of women with acne and hirsutism and is a treatment option for polycystic ovary syndrome (PCOS). It acts as a contraceptive also. Methods: Using the General Practice Research Database, we conducted a cohort analysis and case-control study in women aged 15-39 with acne, hirsutism or PCOS to estimate the risk of liver disorders associated with CPA/EE. Results: Compared with cases exposed to conventional combined oral contraceptives (COCs), the age-adjusted incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (95{\%}CI: 0.9,3.4) and compared with no use it was 1.5 (95{\%}CI: 0.8, 2.8). In the case-control study, the adjusted odds ratio (OR) for liver disorders in women exposed to CPA/EE was 1.6 (95{\%}CI: 0.7, 3.5) and 0.8 (95{\%}CI: 0.5, 1.3) for exposure to conventional COCs, compared with no use. The risk of liver disorders in women prescribed CPA/EE was not significantly greater than that in women prescribed conventional COCs (OR: 2.1 [95{\%}CI: 0.9, 4.8]). Conclusion: Our results do not indicate an increased risk for liver disorders associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting for potential confounding. This may be due to lack of statistical power.",
author = "Seaman, {H E} and {de Vries}, {Corinne S} and Farmer, {R D T}",
year = "2003",
month = "10",
doi = "10.1002/pds.857",
language = "English",
volume = "12",
pages = "541--550",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD

AU - Seaman, H E

AU - de Vries, Corinne S

AU - Farmer, R D T

PY - 2003/10

Y1 - 2003/10

N2 - Purpose: To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the treatment of women with acne and hirsutism and is a treatment option for polycystic ovary syndrome (PCOS). It acts as a contraceptive also. Methods: Using the General Practice Research Database, we conducted a cohort analysis and case-control study in women aged 15-39 with acne, hirsutism or PCOS to estimate the risk of liver disorders associated with CPA/EE. Results: Compared with cases exposed to conventional combined oral contraceptives (COCs), the age-adjusted incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (95%CI: 0.9,3.4) and compared with no use it was 1.5 (95%CI: 0.8, 2.8). In the case-control study, the adjusted odds ratio (OR) for liver disorders in women exposed to CPA/EE was 1.6 (95%CI: 0.7, 3.5) and 0.8 (95%CI: 0.5, 1.3) for exposure to conventional COCs, compared with no use. The risk of liver disorders in women prescribed CPA/EE was not significantly greater than that in women prescribed conventional COCs (OR: 2.1 [95%CI: 0.9, 4.8]). Conclusion: Our results do not indicate an increased risk for liver disorders associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting for potential confounding. This may be due to lack of statistical power.

AB - Purpose: To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the treatment of women with acne and hirsutism and is a treatment option for polycystic ovary syndrome (PCOS). It acts as a contraceptive also. Methods: Using the General Practice Research Database, we conducted a cohort analysis and case-control study in women aged 15-39 with acne, hirsutism or PCOS to estimate the risk of liver disorders associated with CPA/EE. Results: Compared with cases exposed to conventional combined oral contraceptives (COCs), the age-adjusted incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (95%CI: 0.9,3.4) and compared with no use it was 1.5 (95%CI: 0.8, 2.8). In the case-control study, the adjusted odds ratio (OR) for liver disorders in women exposed to CPA/EE was 1.6 (95%CI: 0.7, 3.5) and 0.8 (95%CI: 0.5, 1.3) for exposure to conventional COCs, compared with no use. The risk of liver disorders in women prescribed CPA/EE was not significantly greater than that in women prescribed conventional COCs (OR: 2.1 [95%CI: 0.9, 4.8]). Conclusion: Our results do not indicate an increased risk for liver disorders associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting for potential confounding. This may be due to lack of statistical power.

UR - http://dx.doi.org/10.1002/pds.857

U2 - 10.1002/pds.857

DO - 10.1002/pds.857

M3 - Article

VL - 12

SP - 541

EP - 550

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 7

ER -